Kilmister Ethan John, Robinson Bridget, De Tommasi Claudio
Department of Neurosurgery, Christchurch, New Zealand.
Department of Medicine Christchurch Hospital, Christchurch, New Zealand.
Surg Neurol Int. 2021 Oct 19;12:529. doi: 10.25259/SNI_788_2021. eCollection 2021.
Ganglioglioma (GG) of the third ventricle is rare. Surgical excision of tumors in this location is associated with high morbidity due to nearby eloquent brain centers. Alternative treatments, when available, should be considered to reduce risks of surgical treatment.
We present the case of a 21-year-old female diagnosed with a BRAF V600E mutated GG of the third ventricle. After an endoscopic biopsy and insertion of a ventriculoperitoneal shunt, the patient was started on the inhibitor dabrafenib, as an alternative to surgery or radiation. Nearly 2 years after starting dabrafenib, her tumor appearance on serial magnetic resonance imaging is stable, and she has maintained a good quality of life with no new neurological symptoms.
The disease control thus far suggests targeted medical therapy of GG of the third ventricle with inhibitors may have efficacy and should be a considered treatment modality.
第三脑室神经节胶质瘤（GG）较为罕见。由于该部位附近有明确的脑功能中心，在此处进行肿瘤手术切除会导致较高的发病率。如有其他可用的治疗方法，应考虑采用以降低手术治疗风险。
我们报告一例21岁女性，被诊断为第三脑室BRAF V600E突变型GG。在内镜活检并插入脑室腹腔分流管后，患者开始使用抑制剂达拉非尼，作为手术或放疗的替代方案。开始使用达拉非尼近2年后，她在系列磁共振成像上的肿瘤表现稳定，并且维持了良好的生活质量，没有出现新的神经症状。
迄今为止的疾病控制情况表明，用抑制剂对第三脑室GG进行靶向药物治疗可能有效，应作为一种可考虑的治疗方式。
